Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02616250 · ClinicalTrials.gov registry record · Phase 4
MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 190
- Enrollment target
NCT02616250 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 190 participants.
The verdict
NCT02616250, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 190 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea.
Interventions
- DRUG Brimonidine 0.33% gel (Br)
- OTHER CD07805/47 (Br) placebo gel
- DRUG Ivermectin 1% cream (IVM)
- OTHER CD5024 (IVM) placebo cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02616250
The ClinicalTrials.gov registry entry for NCT02616250 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Brimonidine 0.33% gel (Br) is the first listed.
NCT02616250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02616250 about?
NCT02616250 is a clinical study titled "MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.". The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea.
What is the current status of trial NCT02616250?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 190 participants. The study started on 2015-12. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02616250?
The interventions under investigation include: Brimonidine 0.33% gel (Br) (DRUG), CD07805/47 (Br) placebo gel (OTHER), Ivermectin 1% cream (IVM) (DRUG), CD5024 (IVM) placebo cream (OTHER).
Who is sponsoring clinical trial NCT02616250?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.